Tags: Drug.

JD5037 is an antiobesity drug candidate which acts as a peripherally-restricted cannabinoid inverse agonist at CB1 receptors. It is very selective for the CB1 subtype with a Ki of 0.35nM >700-fold higher affinity than it has for CB2 receptors.In animal studies JD5037 does not readily cross the blood brain barrier and thus is not expected to produce the psychiatric side effects in humans which led to the withdrawal of rimonabant from the market.

JD5037_skeletal.png
IUPAC name
(S)-2-((SE)-3-(4-chlorophenyl)-N'-((4-chlorophenyl)sulfonyl)-4-phenyl-45-dihydro-1H-pyrazole-1-carboximidamido)-3-methylbutanamide

Loading...

This page contains content from the copyrighted Wikipedia article "JD5037"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.